The Study
KRAS mutation: from undruggable to druggable in cancer
This article is like a summary of a bunch of science news stories—it tells you what other scientists have found, but it doesn’t do any new experiments itself. So it can tell you what’s been tried and what seems promising, but it can’t prove that a drug definitely works or causes tumors to shrink.
Analysis score
Maximum 5 for a narrative review.
Where the score came from
For 40 years, scientists couldn't find a way to stop a broken gene called KRAS that makes cancer grow. Then, they found a special trick to block just one version of it, called KRAS(G12C), using pills that latch onto it like a key.
Where does this study sit?
Systematic Reviews & Meta-analyses
Max 100Randomized Trials
Max 90Cohort Studies
Max 72Case-Control
Max 58Cross-Sectional
Max 44Case Reports & Series
Max 30Expert Opinion
Max 52 / 100
Quality score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — for patients with advanced lung cancer who had run out of other treatments, this meant a real chance to live longer with fewer side effects than chemo.
- 2In patients with this specific mutation, about 1 in 3 had their tumors shrink, and most others had their cancer stop growing for about 6–7 months.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Signal Transduction and Targeted Therapy
Year
2021
Authors
Lamei Huang, Zhixing Guo, Fang Wang, Liwu Fu
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.